Ranbaxy Can't Split Antitrust Claims From Provigil Trial
Ranbaxy Laboratories Inc. lost a bid to split certain claims from an upcoming trial in pay-for-delay litigation over sleep-disorder medicine Provigil when a Pennsylvania federal judge found Friday that the claims...To view the full article, register now.
Already a subscriber? Click here to view full article